Oxford Biomedica plc (OXB.L) Monday said its loss before tax from continuing operations for the full year widened to 188.53 million pounds from 45.98 million pounds loss in the previous year, primarily due to decline in revenue.
Net loss was 157.49 million pounds or 163.11p per share compared with loss of 39.16 million pounds or 41.29p per share last year.
Revenue for the year decreased 36 percent to 89.54 million pounds from 139.99 million pounds a year ago impacted by the non-recurrence of vaccine manufacturing revenues.
Looking ahead, the company has reaffirmed its fiscal 2024 outlook. It still sees revenue for 2024 to be in the range of 126 million pounds - 134 million pounds.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.